HLS Therapeutics (TSE:HLS) Issues Quarterly Earnings Results

HLS Therapeutics (TSE:HLS) released its earnings results on Thursday. The company reported C($0.05) EPS for the quarter, FiscalAI reports. The company had revenue of C$20.06 million for the quarter. HLS Therapeutics had a negative net margin of 25.28% and a negative return on equity of 21.20%.

HLS Therapeutics Stock Performance

Shares of TSE:HLS opened at C$4.27 on Thursday. The business’s fifty day moving average price is C$4.57 and its two-hundred day moving average price is C$5.03. The company has a debt-to-equity ratio of 87.61, a current ratio of 1.17 and a quick ratio of 1.01. HLS Therapeutics has a fifty-two week low of C$3.90 and a fifty-two week high of C$5.77. The stock has a market capitalization of C$133.54 million, a price-to-earnings ratio of -9.49 and a beta of 0.48.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.